US02043Q1076 - Common Stock
Alnylam Pharmaceuticals announces positive Phase 2 study results for zilebesiran, a potential treatment for hypertension and high cardiovascular risk.
San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
The company can begin a pivotal study of its treatment for cardiomyopathy.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
Oppenheimer downgrades Alnylam Pharmaceuticals as it prepares to release data from its HELIOS-B study for amyloidosis therapyvutrisiran early next year. Read more here.
The FDA rejection of Alnylam's amyloidosis therapy impacts Arbutus Biopharma, which has a licensing deal with the company for the product. Read more here.
Shares skidded to their lowest point since September on the FDA's rejection.
Potential approvals of new medicines expected soon could push these stocks through the roof.
Raymond James initiated coverage on Ionis Pharmaceuticals, AbbVie, and Alnylam Pharmaceuticals with buy-equivalent ratings. Read more here.
Alnylam (ALNY) stock was down 8% Thursday, the day after an FDA advisory panel questioned the effectiveness of its drug patisiran in treating ATTR-CM. Read more here.